Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-15T12:50:47.104Z Has data issue: false hasContentIssue false

83 A Bayesian framework for efficacy-and-effectiveness too randomized clinical trials with dynamic borrowing

Published online by Cambridge University Press:  08 May 2026

Jonathan Huang
Affiliation:
Tufts University
Ludovic Trinquart
Affiliation:
Tufts University Clinical and Translational Science Institute (CTSI); Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Objectives/Goals: Efficacy-and-Effectiveness Too (EE2) randomized clinical trials pair a controlled efficacy cohort with a pragmatic effectiveness cohort. We will deliver a Bayesian EE2 framework with interim go/no-go rules and adaptive cross-cohort borrowing for time-to-event endpoints. Methods/Study Population: We formalize three approaches: 1) simultaneous: both cohorts start together, and interim looks apply predictive success probability (PSP) to enable early efficacy or futility stopping within each cohort; 2) staggered: the trial begins with the efficacy cohort and, at 50% information, initiates the effectiveness cohort only if the PSP under a retained-effect assumption (e.g., ≥70% of the efficacy log-HR retained) exceeds a prespecified threshold; 3) sequential: the efficacy trial is completed first, and the effectiveness trial is designed using the efficacy posteriors. Across approaches, the Bayesian method relies on piecewise-exponential modeling with Gamma-Poisson conjugacy, Negative-Binomial predictive counts, and power or commensurate priors with robust discounting. Results/Anticipated Results: Operating characteristics (type I error, power, bias/coverage, borrowing Effective Sample Size) will be evaluated through simulation studies across heterogeneity scenarios and prior-data conflict. We will re-analyze the RUBY and NRG-GY018 endometrial trials (endpoints: Progression-Free Survival and Overall Survival) as EE2 case studies (efficacy: mismatch repair-deficient tumors; effectiveness: mismatch repair-proficient tumors) using dynamic borrowing and the appropriate interim logic to demonstrate feasibility, robustness, and gains in precision. We anticipate improved precision for each cohort and for the combined effect and stable decisions under partial retention. Discussion/Significance of Impact: This work provides the first end-to-end Bayesian EE2 toolkit spanning simultaneous, staggered, and sequential implementations, with interim rules, principled borrowing, and software, to accelerate the generation of generalizable evidence while safeguarding against prior-data conflict, advancing efficient, patient-centered translation.

Information

Type
Biostatistics, epidemiology, and research design
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2026. The Association for Clinical and Translational Science